Evidence map›Paper›PMID 41239300›Full record

ArticleBMC infectious diseases2025

The impact of fluoroquinolone-resistant enterobacterales colonization on fluoroquinolone prophylaxis efficacy in hematopoietic cell transplant recipients.

Rima Moghnieh, Ahmad Khalil, Antoine Khoury, Hilal Abdessamad, Pamela Sfeir, Mariana Mezher, Monica Abi Abdallah, Bilal Hamade, Kamal Zahran, Edmond Abboud and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rima MoghniehLebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon. moghniehrima@gmail.com.
Ahmad KhalilUniversity of Balamand, Alkoura, Lebanon.
Antoine KhouryUniversity of Balamand, Alkoura, Lebanon.
Hilal AbdessamadLebanese American University, Byblos, Lebanon.
Pamela SfeirMiddle East Institute of Health, Bsalim, Lebanon.
Mariana MezherMiddle East Institute of Health, Bsalim, Lebanon.
Monica Abi AbdallahMiddle East Institute of Health, Bsalim, Lebanon.
Bilal HamadeMiddle East Institute of Health, Bsalim, Lebanon.
Kamal ZahranMiddle East Institute of Health, Bsalim, Lebanon.
Edmond AbboudMiddle East Institute of Health, Bsalim, Lebanon.
Aysar FakihLebanese American University, Byblos, Lebanon.
Rana AttiehLebanese American University, Byblos, Lebanon.
Farah HneiniLebanese American University, Byblos, Lebanon.
Marilyne SilyLebanese American University, Byblos, Lebanon.
Wael ZorkotLebanese University, Beirut, Lebanon.
Shadi EidLebanese American University, Byblos, Lebanon.
Dania AbdallahMakassed General Hospital, Beirut, Lebanon.
Ahmad IbrahimUniversity of Balamand, Alkoura, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHematopoietic cell transplantation (HCT) carries a high infection risk, especially pre-engraftment. Fluoroquinolone (FQ) prophylaxis is common, but rising FQ-resistant Enterobacterales (FQRE) rates may limit its effectiveness. This study evaluated febrile neutropenia, bacteremia, and mortality in HCT patients based on FQ prophylaxis and FQRE colonization.

methodsA retrospective analysis of HCT recipients at a tertiary center in Lebanon (2017–2022) was performed. Patients receiving FQ prophylaxis during neutropenia were compared with those who did not. FQRE colonization was monitored through weekly perianal swabs post-transplant.

resultsOf 156 HCT recipients (mean age 54 years; 61% males), 73.1% received FQ prophylaxis, and 39% had FQRE colonization. Febrile neutropenia occurred in 86%, more frequently in non-prophylaxis and FQRE-colonized patients, though prophylaxis delayed its onset within 10 days post-transplant. Bacteremia affected 39.1% of 64 eligible patients, with lower rates in the prophylaxis group (35.7% vs. 62.5%, p = 0.02). Escherichia coli and coagulase-negative staphylococci predominated. All-cause mortality was 3.8%, with pneumonia and Clostridioides difficile infections in 5.1% and 3.2%, respectively; prophylaxis showed non-significant reductions in these outcomes.

conclusionFQ prophylaxis reduced febrile neutropenia and bacteremia in HCT recipients, including those colonized with FQRE. Larger studies are needed to confirm its effects on multiple outcomes. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Anti-Bacterial AgentsAntibiotic ProphylaxisDrug Resistance, BacterialEnterobacteriaceaeEnterobacteriaceae InfectionsFluoroquinolonesHematopoietic Stem Cell TransplantationAdultAgedBacteremiaFebrile NeutropeniaFemaleHumansLebanonMaleMiddle AgedAnti-Bacterial AgentsFluoroquinolonesAllogeneic hematopoietic cell transplantationAntibiotic prophylaxisAutologous hematopoietic cell transplantationFebrile neutropeniaFluoroquinoloneFluoroquinolone-resistant enterobacteralesLebanonPre-engraftment bacteremia

Identifiers

PMID41239300
PMCPMC12619514

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.